Voyager Therapeutics is a biotechnology business based in the US. Voyager Therapeutics shares (VYGR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.36 – a decrease of 13.83% over the previous week. Voyager Therapeutics employs 162 staff and has a trailing 12-month revenue of around $163.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.36 |
|---|---|
| 52-week range | $5.59 - $11.72 |
| 50-day moving average | $6.63 |
| 200-day moving average | $7.83 |
| Wall St. target price | $17.33 |
| PE ratio | 23.037 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.27 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.27 from 2024-11-19
| 1 week (2024-11-13) | -21.23% |
|---|---|
| 1 month (2024-10-18) | -34.70% |
| 3 months (2024-08-20) | -24.17% |
| 6 months (2024-05-20) | -37.63% |
| 1 year (2023-11-20) | -22.95% |
|---|---|
| 2 years (2022-11-18) | -2.41% |
| 3 years (2021-11-19) | 60.18% |
| 5 years (2019-11-20) | 14.51 |
Valuing Voyager Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Voyager Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Voyager Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Voyager Therapeutics shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Voyager Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14.1 million.
The EBITDA is a measure of a Voyager Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $163.8 million |
|---|---|
| Gross profit TTM | $-19,857,000 |
| Return on assets TTM | 1.57% |
| Return on equity TTM | 10.22% |
| Profit margin | 15.8% |
| Book value | $6.06 |
| Market Capitalization | $339.8 million |
TTM: trailing 12 months
We're not expecting Voyager Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Voyager Therapeutics's shares have ranged in value from as little as $5.5901 up to $11.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Voyager Therapeutics's is 0.889. This would suggest that Voyager Therapeutics's shares are less volatile than average (for this exchange).
Voyager Therapeutics, Inc. , a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.